- CDC reports epilepsy is growing problem, 3.4 million people afflicted in the US
- According to report, adult cases rose from 2.3 million to 3 million between 2010 and 2015, pediatric cases increased 450,000 to 470,000 over same period
- Brain Scientific produces patented devices that can be used to provide instant EEG tests to millions of US hospital patients each year
More Americans are suffering from epilepsy than ever before, according to a report by the Center for Disease Control (“CDC”) that states that at least 3.4 million people live with the disorder in the United States (
https://ibn.fm/PmF2b).
Brain Scientific (OTCQB: BRSF), a New York City based commercial stage healthcare company, aims to address the problem with two FDA-cleared products that can be used to provide instant electroencephalogram (“EEG”) tests to millions of patients subject to seizures in US hospitals each year.
According to Brain Scientific’s corporate presentation (
https://ibn.fm/IQ6xG), roughly four million emergency department and one million ICU patients are possibly subjected to seizures each year, and that number is expected to rise significantly. The CDC confirms the rising incidence of the disease with statistics from 2015 stating that adult cases rose from 2.3 million to 3 million between 2010 and 2015, and pediatric cases increased 450,000 to 470,000 over the same period.
“Millions of Americans are impacted by epilepsy, and unfortunately, this study shows cases are on the rise,” said CDC Director Brenda Fitzgerald, M.D. “Proper diagnosis is key to finding an effective treatment – and at CDC we are committed to researching, testing, and sharing strategies that will improve the lives of people with epilepsy.”
With patents already approved in the United States, China and Europe, Brain Scientific’s first commercialized devices – the NeuroCap(TM) and NeuroEEG(TM) – offer low-cost, disposable and portable alternatives to existing time-intensive and costly solutions. The NeuroCap is a disposable pre-gelled EEG headset that features 22 electrodes and 19 active EEG channels that adhere to the international 10-20 system, and the NeuroEEG is a compact, portable, and cost-effective clinical-grade wireless EEG amplifier. Used together both devices can acquire, record, display and transmit electrical brain activity in nearly any setting, including urban emergency departments, intensive care units, community and rural hospitals, neurology practices, primary care/internal medicine clinics, pain management clinics, sleep labs, nursing homes, and mobile diagnostic and treatment clinics.
Brain Scientific intends to take its devices beyond on-site brain diagnostic imaging with the use of cloud-powered technology and artificial intelligence (“AI”) and machine learning (“ML”) algorithms that will enable precision diagnosis by neurology specialists.
Founded in 2015, Brain Scientific and its wholly owned subsidiary MemoryMD Inc. went public in 2018. The Company is dedicated to developing innovative, cost-effective, and portable medical devices that aim to expand the neurology market and make brain diagnostic imaging increasingly accessible to a large range of diverse, rapidly growing markets.
For more information, visit the company’s website at
www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at
https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit
https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the
InvestorBrandNetwork.